What is the ROE (Return on Equity) of CardieX this year?
The ROE of CardieX this year is 25.24 undefined.
CardieX ROE 2024
CardieX ROE
25.24
Ticker
CDX.AX
ISIN
AU0000015729
WKN
A2JN9Z
In 2024, CardieX's return on equity (ROE) was 25.24, a -1,512.78% increase from the -1.79 ROE in the previous year.
CardieX Aktienanalyse
What does CardieX do?
Cardiex Ltd is an Australian medical technology company specializing in the development and marketing of cardiovascular monitoring systems and diagnostic tools. The company was founded in 1996 and is based in Melbourne. Cardiex's history begins with the development of SphygmoCor technology in collaboration with researchers from Monash University. This technology allows for non-invasive measurement of pulse and blood pressure waves in the arteries, providing information about the condition of the cardiovascular system. Cardiex's first product was the SphygmoCor Analyzer, which was launched in 1999. Over time, additional products and technologies have been developed to meet the growing demand for cardiovascular monitoring and diagnostics. Cardiex's business model is based on the development and marketing of innovative medical technologies for the international market. The company works closely with clinics, research institutions, and medical device manufacturers to develop products that meet the needs of the healthcare sector. Cardiex has a comprehensive network of sales and marketing partners in over 40 countries worldwide. Cardiex operates in several divisions, including: - Diagnostic Systems: This division includes products such as the SphygmoCor Analyzer, which assesses arterial health, and the Arterial Stiffness Scanner, which enables early detection of cardiovascular risk factors. - Telemedicine: Cardiex offers a telehealth platform that allows clinics and medical personnel to monitor and analyze patient data in real-time. The platform can be used for remote patient monitoring, early detection of complications, and treatment optimization. - Research and Development: Cardiex collaborates closely with researchers and medical institutions to develop new technologies for cardiovascular monitoring and diagnostics. The company invests heavily in research and development to maintain a leading role in the field of medical technology. An important aspect of Cardiex's business model is its partnership with other companies. The company works closely with device manufacturers, software developers, and other service providers to integrate its technologies and products, offering complete solutions for the healthcare sector. Cardiex's products include not only the SphygmoCor Analyzer but also the Arterial Stiffness Scanner, Ambulatory Blood Pressure Monitor, CardiexCare data management system, and telehealth platform. All these products are designed to simplify and improve the monitoring and diagnosis of cardiovascular diseases. Overall, Cardiex is a successful medical technology company specializing in the development and marketing of innovative cardiovascular monitoring systems and diagnostic tools. The company has expanded its product and service offerings in recent years and has a strong international presence. Through close collaboration with other companies and research institutions, Cardiex will continue to play a leading role in the field of medical technology in the future. CardieX ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding CardieX's Return on Equity (ROE)
CardieX's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing CardieX's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
CardieX's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in CardieX’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about CardieX stock
How has the Return on Equity (ROE) of CardieX developed compared to the previous year?
The ROE of CardieX has increased by -1,512.78% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of CardieX?
A high ROE indicates that CardieX generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of CardieX?
A low ROE can indicate that CardieX is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of CardieX affect the company?
A change in ROE (Return on Equity) of CardieX can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of CardieX?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of CardieX?
Some factors that can influence CardieX's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does CardieX pay?
Over the past 12 months, CardieX paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CardieX is expected to pay a dividend of 0 AUD.
What is the dividend yield of CardieX?
The current dividend yield of CardieX is .
When does CardieX pay dividends?
CardieX pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of CardieX?
CardieX paid dividends every year for the past 0 years.
What is the dividend of CardieX?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is CardieX located?
CardieX is assigned to the 'Health' sector.
Wann musste ich die Aktien von CardieX kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of CardieX from 9/19/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/19/2024.
When did CardieX pay the last dividend?
The last dividend was paid out on 9/19/2024.
What was the dividend of CardieX in the year 2023?
In the year 2023, CardieX distributed 0 AUD as dividends.
In which currency does CardieX pay out the dividend?
The dividends of CardieX are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von CardieX
Our stock analysis for CardieX Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CardieX Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
